Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dylan Martini, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Martini DJ, Goyal S, Switchenko JM, Lechowicz MJ, Allen PB. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center. Leuk Lymphoma. 2022 Apr 28; 1-8. PMID: 35481397.
    Citations:    Fields:    
  2. Martini DJ, Chen YB, DeFilipp Z. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. Oncologist. 2022 Apr 20. PMID: 35443042.
    Citations:    Fields:    
  3. Olsen TA, Zhuang TZ, Caulfield S, Martini DJ, Brown JT, Carthon BC, Kucuk O, Harris W, Bilen MA, Nazha B. Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy. Front Endocrinol (Lausanne). 2022; 13:779915. PMID: 35392134.
    Citations:    Fields:    Translation:Humans
  4. Bidot S, Monsrud A, Kline M, Speak A, Martini D, Bilen MA, Switchenko JM, Zhang Y, Gerges AG, Farhat GN, Dent EA, Master VA, Tinsley ML, Harik LR. Risk Stratification of Prostatic Adenocarcinoma Metastatic to the Lymph Nodes. Arch Pathol Lab Med. 2022 Feb 10. PMID: 35142822.
    Citations:    Fields:    
  5. Martini DJ, Jansen CS, Harik LR, Evans ST, Olsen TA, Master VA, Kissick HT, Bilen MA. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Front Oncol. 2021; 11:793808. PMID: 34976834.
    Citations:    
  6. Martini DJ, Evans ST, Liu Y, Shabto JM, Uner OE, Olsen TA, Brown JT, Russler GA, Yantorni L, Caulfield S, Goldman JM, Nazha B, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. Clin Genitourin Cancer. 2022 02; 20(1):53-59. PMID: 34922840.
    Citations:    Fields:    Translation:Humans
  7. Martini DJ, Shabto JM, Goyal S, Liu Y, Olsen TA, Evans ST, Magod BL, Ravindranathan D, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Nazha B, Joshi SS, Kissick HT, Ogan KE, Harris WB, Kucuk O, Carthon BC, Master VA, Bilen MA. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist. 2021 12; 26(12):1017-1025. PMID: 34342095.
    Citations:    Fields:    Translation:Humans
  8. Marks JA, Switchenko JM, Martini DJ, Tarabadkar ES, Khan MK, Lechowicz MJ, Allen PB. T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma. JAMA Dermatol. 2021 Aug 01; 157(8):954-962. PMID: 34190977.
    Citations:    Fields:    Translation:Humans
  9. Martini DJ, Olsen TA, Goyal S, Liu Y, Evans ST, Magod B, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Nazha B, Kissick HT, Harris WB, Kucuk O, Carthon BC, Master VA, Bilen MA. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Front Oncol. 2021; 11:707050. PMID: 34307176.
    Citations:    
  10. Martini DJ, Goyal S, Liu Y, Evans ST, Olsen TA, Case K, Magod BL, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Nazha B, Harris WB, Kissick HT, Master VA, Kucuk O, Carthon BC, Bilen MA. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2021 10; 26(10):e1742-e1750. PMID: 34156726.
    Citations: 2     Fields:    Translation:Humans
  11. Brown JT, Liu Y, Shabto JM, Martini D, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni L, Joshi SS, Kissick H, Ogan K, Nazha B, Carthon BC, Kucuk O, Harris WB, Master VA, Bilen MA. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7). PMID: 34326170.
    Citations:    Fields:    Translation:Humans
  12. Olsen TA, Martini DJ, Goyal S, Liu Y, Evans ST, Magod B, Brown JT, Yantorni L, Russler GA, Caulfield S, Goldman JM, Harris WB, Kucuk O, Carthon BC, Master VA, Nazha B, Bilen MA. Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Front Oncol. 2021; 11:701345. PMID: 34222024.
    Citations:    
  13. Martini DJ, Kline MR, Liu Y, Shabto JM, Carthon BC, Russler GA, Yantorni L, Hitron EE, Caulfield S, Goldman JM, Harris WB, Kucuk O, Master VA, Bilen MA. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat Res Commun. 2021; 28:100393. PMID: 34029879.
    Citations:    Fields:    Translation:Humans
  14. Higgins MI, Martini DJ, Patil DH, Nabavizadeh R, Steele S, Williams M, Joshi SS, Narayan VM, Sekhar A, Psutka SP, Ogan K, Bilen MA, Master VA. Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer. 2021 06 15; 127(12):1974-1983. PMID: 33760232.
    Citations: 5     Fields:    Translation:Humans
  15. Brown JT, Liu Y, Shabto JM, Martini DJ, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni LB, Joshi SS, Kissick H, Ogan K, Harris WB, Carthon BC, Kucuk O, Master VA, Bilen MA. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):397-405. PMID: 33634507.
    Citations: 4     Fields:    Translation:Humans
  16. Olsen TA, Martini DJ, Evans ST, Goldman JM, Bilen MA. Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report. J Med Case Rep. 2021 Feb 19; 15(1):72. PMID: 33602288.
    Citations:    Fields:    Translation:Humans
  17. Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Bilen MA, El-Rayes BF. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol. 2021 02 01; 44(2):74-81. PMID: 33350681.
    Citations: 9     Fields:    Translation:HumansCells
  18. Higgins MI, Martini DJ, Patil DH, Steele S, Evans S, Petrinec BP, Psutka SP, Sekhar A, Bilen MA, Master VA. Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements. Eur J Radiol. 2020 Nov; 132:109307. PMID: 33010681.
    Citations: 2     Fields:    Translation:Humans
  19. Karabachev AD, Martini DJ, Hermel DJ, Solcz D, Richardson ME, Pesaran T, Sarkar IN, Greenblatt MS. Curated multiple sequence alignment for the Adenomatous Polyposis Coli (APC) gene and accuracy of in silico pathogenicity predictions. PLoS One. 2020; 15(8):e0233673. PMID: 32750050.
    Citations:    Fields:    Translation:HumansCells
  20. McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020 08; 135:203-210. PMID: 32599410.
    Citations: 8     Fields:    Translation:Humans
  21. Martini DJ, Liu Y, Master VA, Harvey RD, Bilen MA. Reply to Body fat indices and survival in immunotherapy-treated patients with cancer. Cancer. 2020 07 01; 126(13):3157-3159. PMID: 32286681.
    Citations:    Fields:    Translation:Humans
  22. Shabto JM, Martini DJ, Liu Y, Ravindranathan D, Brown J, Hitron EE, Russler GA, Caulfield S, Kissick H, Alemozaffar M, Ogan K, Harris WB, Master VA, Kucuk O, Carthon BC, Bilen MA. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer Med. 2020 04; 9(8):2752-2760. PMID: 32100417.
    Citations: 9     Fields:    Translation:Humans
  23. Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer. 2020 02; 8(1). PMID: 32066646.
    Citations: 21     Fields:    Translation:Humans
  24. Martini DJ, Liu Y, Shabto JM, Carthon BC, Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O, Master VA, Bilen MA. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2019 Dec 05. PMID: 31806780.
    Citations:    Fields:    
  25. Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, Khan AI, Speak A, Lewis C, Collins H, Kissick HT, Carthon BC, Akce M, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist. 2020 03; 25(3):e528-e535. PMID: 32162807.
    Citations: 18     Fields:    Translation:Humans
  26. Martini DJ, Liu Y, Shabto JM, Carthon BC, Hitron EE, Russler GA, Caulfield S, Kissick HT, Harris WB, Kucuk O, Master VA, Bilen MA. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2020 03; 25(3):e484-e491. PMID: 32162798.
    Citations: 14     Fields:    Translation:Humans
  27. Martini DJ, Kline MR, Liu Y, Shabto JM, Williams MA, Khan AI, Lewis C, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Master VA, Bilen MA. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer. 2020 02 01; 126(3):575-582. PMID: 31648379.
    Citations: 15     Fields:    Translation:Humans
  28. Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. Eur Urol Oncol. 2020 06; 3(3):372-381. PMID: 31562048.
    Citations: 17     Fields:    Translation:Humans
  29. Bilen MA, Shabto JM, Martini DJ, Liu Y, Lewis C, Collins H, Akce M, Kissick H, Carthon BC, Shaib WL, Alese OB, Steuer CE, Wu C, Lawson DH, Kudchadkar R, Master VA, El-Rayes B, Ramalingam SS, Owonikoko TK, Harvey RD. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019 Aug 29; 19(1):857. PMID: 31464611.
    Citations: 29     Fields:    Translation:Humans
  30. Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Invest New Drugs. 2019 12; 37(6):1198-1206. PMID: 30725388.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  31. Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019 01 01; 125(1):127-134. PMID: 30329148.
    Citations: 53     Fields:    Translation:Humans
  32. McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. Cancer Immunol Res. 2018 07; 6(7):758-765. PMID: 29748390.
    Citations: 41     Fields:    Translation:HumansCells
  33. Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res. 2018 04; 6(4):402-408. PMID: 29437040.
    Citations: 19     Fields:    Translation:Humans
  34. Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5. PMID: 29353553.
    Citations: 82     Fields:    Translation:HumansCells
  35. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG, Choueiri TK, Van Allen EM. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018 Feb 16; 359(6377):801-806. PMID: 29301960.
    Citations: 366     Fields:    Translation:Humans
  36. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017 08 15; 5(1):66. PMID: 28807048.
    Citations: 10     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Martini's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (96)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.